Benefits
MTHFR variant bypass
MTHFR gene variants (C677T, A1298C) reduce folic acid → active folate conversion by 30-70% in 40-50% of the population. Methylfolate bypasses this conversion bottleneck, providing the active form directly. Particularly useful for those with known MTHFR variants on genetic testing.
Homocysteine reduction
Methylfolate combined with B12 and B6 reduces elevated homocysteine — a cardiovascular risk marker. Effect sizes are well-documented and clinically meaningful for cardiovascular risk reduction in those with elevated homocysteine.
Pregnancy and preconception folate
Adequate folate is essential for preventing neural tube defects. Methylfolate provides this in active form, particularly important for women with MTHFR variants who may not adequately convert synthetic folic acid. CDC and ACOG support either form during pregnancy.
Depression adjunct support
L-methylfolate at higher doses (7.5-15 mg) is FDA-approved as a medical food adjunct to SSRIs for major depression. Effect sizes are modest but useful for SSRI partial responders. This is high-dose pharmaceutical use, not standard supplementation.
B12 and methylation cycle support
Methylfolate is a critical cofactor in the methylation cycle that produces methionine, SAMe, and downstream methyl donors. Supports DNA methylation, neurotransmitter synthesis, and other methylation-dependent processes.
Cognitive function in aging
Emerging evidence suggests methylfolate may support cognitive function in older adults, particularly when combined with B12. Mechanism involves homocysteine reduction and methylation cycle support. Less established than the cardiovascular applications.
Folic acid vs methylfolate context
Folic acid works fine for the 50-60% of population without MTHFR variants. The 'everyone needs methylfolate' marketing is overstated. Worth using methylfolate when MTHFR status is known to be variant or for specific clinical applications. Otherwise folic acid is much cheaper and equally effective.
Mechanism of action
End-Product of Folate Metabolism
Folic acid → DHF → THF → 5,10-methyleneTHF → 5-MTHF (via MTHFR). Methylfolate IS 5-MTHF — bypasses all upstream conversions including the rate-limiting MTHFR step.
Methionine Cycle / Homocysteine Conversion
5-MTHF + homocysteine → methionine + THF (via methionine synthase, B12-dependent). Methionine becomes SAMe — universal methyl donor for >100 methyltransferase reactions.
MTHFR Variant Biology
C677T variant: ~70% reduced enzyme activity (homozygous); ~35% reduced (heterozygous). A1298C variant: similar reduction. Combined CT/AC genotype reduces activity ~50-70%. Affects ~25-50% of population varying by ethnicity (higher in Hispanic, Mediterranean populations).
Neurotransmitter Synthesis
Methylfolate provides methyl groups for tetrahydrobiopterin (BH4) regeneration — BH4 is cofactor for tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in dopamine and serotonin synthesis.
Clinical trials
Two sequential clinical trials of L-methylfolate (7.5-15 mg) augmentation to SSRIs in SSRI-resistant major depressive disorder. (Am J Psychiatry)
SSRI-resistant MDD patients.
L-methylfolate 15 mg/day significantly improved depression scores vs SSRI alone in second trial. 7.5 mg dose did not separate from placebo. FDA medical food status (Deplin®) granted based on this evidence. Subgroup with low folate or high BMI/inflammation responded best.
Comparative trial of L-5-MTHF vs folic acid for homocysteine reduction in healthy women.
Healthy women.
Both forms reduced homocysteine; L-5-MTHF produced higher plasma folate levels than equivalent folic acid dose. Particularly notable in MTHFR C677T variant carriers — methylfolate bypasses the impaired enzyme.